SOPHiA GENETICS Initiates Public Offering of Ordinary Shares

The Boston and Rolle-based company confirmed that the offering remains subject to prevailing market conditions and other customary terms. Because the final size and structure of the deal are not yet fixed, the company provided no guarantees regarding the completion or specific timing of the transaction. TD Cowen is serving as the lead book-running manager for the offering.

Legal filings for the move were already established through a registration statement on Form F-3, which the U.S. Securities and Exchange Commission declared effective on August 15, 2025. Access to the preliminary prospectus supplement will be provided through the SEC website or by contacting TD Securities (USA) LLC. The company explicitly noted that these securities will not be offered or sold within Switzerland, as the current release does not constitute a prospectus under the Swiss Financial Services Act.